Neuroendocrine tumors, including small cell lung cancer and neuroendocrine prostate cancer, are very aggressive with high chances of spreading. However, many individuals develop resistance to few ...
Akari Therapeutics is advancing its research on a novel spliceosome modulator, PH1, which has shown potential in killing cancer cells and activating the immune system. The company is focusing on the ...
Researchers have developed a near-single-cell resolution spatial transcriptomic approach to study developmentally regulated RNA processes.
Researchers in the Landau lab, led by Dr. Dan Landau, hematology and medical oncology, recently developed a new technique to investigate how mutations in RNA splicing can lead to clonal hematopoiesis ...
Akari Therapeutics plc announced that it is continuing key research on its antibody-drug conjugate (ADC) payload PH1 to further demonstrate its ability to target cancers fueled by oncogenic drivers.
RNA splicing is a cellular process that is critical for gene expression. After genes are copied from DNA into messenger RNA, portions of the RNA that don't code for proteins, called introns, are cut ...
Graphical abstracts. REST_SSO directly modifies REST splicing and RE1 gene expression, whereas both REST_SSO and SRRM4_ASO exhibit antitumor effects in SCLC/NEPCa. Osaka, Japan – Neuroendocrine tumors ...
RNA splicing is a cellular process that is critical for gene expression. After genes are copied from DNA into messenger RNA, portions of the RNA that don't code for proteins, called introns, are cut ...
Biologists have discovered a new type of RNA-splicing regulation that helps to determine which protein-coding exons will be included in messenger RNA transcripts. RNA splicing is a cellular process ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results